VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...

Processa Pharmaceuticals ( ($PCSA) ) has issued an update. Processa Pharmaceuticals held a Special Meeting of Shareholders on September 11, 2025, ...

HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today ...

Processa Pharmaceuticals announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objecti ...

The latest price target for Processa Pharmaceuticals (NASDAQ:PCSA) was reported by HC Wainwright & Co. on December 5, 2024. The analyst firm set a price target for $6.00 expecting PCSA to rise to ...

HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect Processa Pharmaceuticals to ...

HANOVER, MD, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean based ...

Processa Pharmaceuticals, Inc. has successfully completed a public offering, raising $5 million to support its development of next-generation chemotherapeutic drugs aimed at improving efficacy and ...

HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to ...

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital ...